Delivering timely service and evidence-informed resources to people in BC and the Yukon facing cancer and those involved in oncology care or research.
Contents:; Introduction -- When to refer a patient for CAR-T cell therapy -- Optimizing the apheresis product -- CAR T cells: cell processing laboratory considerations -- Peri-CAR-T cell management -- Management of cytokine release syndrome -- Special considerations for ICU management of patients r…
c.1 BC Cancer Agency VAN Library | Available | ||
c.1 BC Cancer Agency ARHCC Library | Available | ||
c.1 BC Cancer Agency VIC Library | Available |
c.1 BC Cancer Agency VAN Library | Available |
c.1 BC Cancer Agency ARHCC Cancer Info Ctr | Available | ||
c.1 BC Cancer Agency VAN Library | Available | ||
c.1 BC Cancer Agency VIC Cancer Info Ctr | Available | ||
c.2 BC Cancer Agency VIC Cancer Info Ctr | Available | ||
c.1 BC Cancer Agency KEL Cancer Info Ctr | Available |
c.1 BC Cancer Agency VIC Cancer Info Ctr | Available | ||
c.2 BC Cancer Agency VIC Cancer Info Ctr | Available | ||
c.1 BC Cancer Agency VAN Library | Available | ||
c.1 BC Cancer Agency ARHCC Cancer Info Ctr | Available | ||
c.1 BC Cancer Agency PG Cancer Info Ctr | Available | ||
c.1 BC Cancer Agency KEL Cancer Info Ctr | Available |
c.1 BC Cancer Agency ARHCC Cancer Info Ctr | Available | ||
c.1 BC Cancer Agency PG Cancer Info Ctr | Available | ||
c.1 BC Cancer Agency SUR Cancer Info Ctr | Available | ||
c.1 BC Cancer Agency VAN Cancer Info Ctr | Available | ||
c.2 BC Cancer Agency VAN Cancer Info Ctr | Available | ||
c.2 BC Cancer Agency ARHCC Cancer Info Ctr | Available |
"Clinical and preclinical exploration of gene and cellular immunotherapy have seen rapid growth and interest with the development and approval of five Chimeric Antigen Receptor T-cell (CAR-T) products for lymphoma and myeloma and one Bispecific T-Cell Engager (BiTE) for acute lymphoblastic leukemia…
c.1 BC Cancer Agency VAN Library | Available |
c.1 BC Cancer Agency VAN Library | Available |
c.1 BC Cancer Agency VAN Library | Available |
c.2 BC Cancer Agency VIC Cancer Info Ctr | On Loan, due Tuesday, February 20, 2024 | ||
c.1 BC Cancer Agency VAN Library | Available | ||
c.1 BC Cancer Agency ARHCC Cancer Info Ctr | Available | ||
c.1 BC Cancer Agency PG Cancer Info Ctr | Available | ||
c.1 BC Cancer Agency SUR Cancer Info Ctr Missing | Available | ||
c.1 BC Cancer Agency VAN Cancer Info Ctr | Available | ||
c.1 BC Cancer Agency VIC Cancer Info Ctr Missing | Available |
c.1 BC Cancer Agency KEL Cancer Info Ctr | Available |
c.1 BC Cancer Agency ARHCC Cancer Info Ctr | Available |
Definition of primary intraocular lymphoma.; History of primary intraocular lymphoma (1950s-1970s).; Classification of lymphomas.; Epidemiology of primary intraocular lymphoma.; Clinical manifestations of PIOL.; Imaging -- Pathology.; Immunology of PIOL.; Diagnostic approaches.; Management and trea…
c.1 BC Cancer Agency VAN Library | Available |
Cytogenetic analysis of malignant lymphoma by Doug Horsman (Chapter 2); Primary extranodal non-Hodgkin's lymphomas by Tamara N. Shenkier and Joseph M. Connors (Chapter 18)
c.1 BC Cancer Agency VAN Library | Available |
c.1 BC Cancer Agency VAN Cancer Info Ctr | Available |
c.1 BC Cancer Agency VIC Cancer Info Ctr | Available | ||
c.1 BC Cancer Agency ARHCC Cancer Info Ctr | Available | ||
c.1 BC Cancer Agency SUR Cancer Info Ctr | Available | ||
c.1 BC Cancer Agency VAN Library | Available | ||
c.1 BC Cancer Agency VAN Cancer Info Ctr | Available | ||
c.2 BC Cancer Agency PG Cancer Info Ctr | Available | ||
c.1 BC Cancer Agency PG Cancer Info Ctr Missing | Available |
c.1 BC Cancer Agency VAN Library | Available |
Full conference information obtained from the Annual cancer conference program and abstracts. See ID# 15548. (QZ200 B366 2006); Welcome by Dr. Simon Sutcliffe (10 minutes); Lymphoma on two continents : what have we learned (60 minutes)
c.1 BC Cancer Agency VAN Library AV Room | Available | ||
c.1 BC Cancer Agency VIC Library | Available |
c.1 BC Cancer Agency VAN Library | Available |